Skip to content

Nationwide pivotal registry study on mite immunotherapy in allergic rhinitis patients with or without asthma in China (NAVIGATOR)

Nationwide pivotal registry study on mite immunotherapy in allergic rhinitis patients with or without asthma in China (NAVIGATOR)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400084228
Enrollment
Unknown
Registered
2024-05-13
Start date
2024-05-24
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic rhinitis

Interventions

group 1 (Retrospective study):none
group 2 (prospective study):none

Sponsors

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. 5 years = age =65 years 2. IgE mediated allergic rhinitis with or without allergic asthma caused by house dust mite allergens (house dust mites and/or dust mites) 3. If accompanied by bronchial asthma, ensure that their asthma symptoms are well controlled according to GINA 2020 guidelines 4. Received AIT treatment

Exclusion criteria

Exclusion criteria: 1. In the judgment of the investigator, the subject and/or parent/legal guardian are unable to understand and comply with the requirements of the study 2. Patients with severe or uncontrolled asthma (FEV1 <70% predicted value) and irreversible airflow obstruction 3. Patients on beta-blockers or Angiotensin-converting enzyme (ACE) inhibitors 4. Severe autoimmune diseases, including AIDS, inflammatory bowel disease and other immune deficiency diseases and autoimmune diseases, as well as active infection, diabetes, gastric ulcer and other patients 5. Patients with severe psychological disorders or those that can not accept the risk of treatment 6. Suffering from severe cardiovascular disease 7. Cancer 8. pregnancy 9. Poor compliance

Design outcomes

Primary

MeasureTime frame
Skin Prick Tests(SPT);serum IgE;VAS score;Symptom score;Drug scores;AEs information;Emerging Allergens;New-onset asthma;

Countries

China

Contacts

Public ContactZhu rongfei

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

zrf13092@163.com+86 27 8366 2912

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026